Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MPLN Stock Forecast 2025-2026
$29.15
Current Price
$374.98M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MPLN Price Targets
-65.7%
To High Target of $10.00
-65.7%
To Median Target of $10.00
-65.7%
To Low Target of $10.00
MPLN Price Momentum
+6.5%
1 Week Change
+29.2%
1 Month Change
+6.1%
1 Year Change
+97.2%
Year-to-Date Change
-2.3%
From 52W High of $29.84
+507.3%
From 52W Low of $4.80
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching MultiPlan (MPLN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MPLN and similar high-potential opportunities.
Latest MPLN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MPLN has a neutral consensus with a median price target of $10.00 (ranging from $10.00 to $10.00). The overall analyst rating is Buy (7.0/10). Currently trading at $29.15, the median forecast implies a -65.7% downside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniel Grosslight at Citigroup, projecting a 65.7% downside. Conversely, the most conservative target is provided by Daniel Grosslight at Citigroup, suggesting a 65.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MPLN Analyst Ratings
1
Buy
1
Hold
0
Sell
MPLN Price Target Range
Low
$10.00
Average
$10.00
High
$10.00
Current: $29.15
Latest MPLN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MPLN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2025 | Piper Sandler | Neutral | Maintains | $0.00 | |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Neutral | Maintains | $12.50 |
| Sep 23, 2024 | Citigroup | Daniel Grosslight | Neutral | Maintains | $10.00 |
| Aug 7, 2024 | Piper Sandler | Jessica Tassan | Neutral | Reiterates | $1.00 |
| Jun 26, 2024 | Piper Sandler | Jessica Tassan | Neutral | Initiates | $2.00 |
| Mar 8, 2023 | Citigroup | Daniel Grosslight | Neutral | Maintains | $1.25 |
| Jan 18, 2023 | Barclays | Marc Solecitto | Equal-Weight | Maintains | $1.00 |
| Dec 13, 2022 | Citigroup | Daniel Grosslight | Neutral | Downgrade | $2.00 |
| Nov 16, 2022 | Goldman Sachs | Cindy Motz | Neutral | Maintains | $2.05 |
| Nov 9, 2022 | Citigroup | Daniel Grosslight | Buy | Maintains | $3.00 |
| Jul 12, 2022 | Goldman Sachs | Cindy Motz | Neutral | Initiates | $6.50 |
| May 11, 2022 | Citigroup | Daniel Grosslight | Buy | Maintains | $6.50 |
| Dec 20, 2021 | Citigroup | Buy | Maintains | $7.00 | |
| Nov 11, 2021 | Barclays | Steve Valiquette | Equal-Weight | Maintains | $6.00 |
| Aug 20, 2021 | Tigress Financial | Buy | Initiates | $0.00 | |
| Apr 7, 2021 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Apr 7, 2021 | B. Riley FBR | Buy | Initiates | $0.00 | |
| Mar 19, 2021 | Barclays | Equal-Weight | Initiates | $0.00 | |
| Nov 17, 2020 | Citigroup | Buy | Initiates | $0.00 | |
| Nov 16, 2020 | Citigroup | Buy | Initiates | $0.00 |
Claritev Corporation (MPLN) Competitors
The following stocks are similar to MultiPlan based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Claritev Corporation (MPLN) Financial Data
Claritev Corporation has a market capitalization of $374.98M with a P/E ratio of 0.0x. The company generates $930.62M in trailing twelve-month revenue with a -176.9% profit margin.
Revenue growth is -4.9% quarter-over-quarter, while maintaining an operating margin of +5.7% and return on equity of -183.6%.
Valuation Metrics
Market Cap
$374.98M
Enterprise Value
$4.87B
P/E Ratio
0.0x
PEG Ratio
-2.7x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-4.9%
Gross Margin
+75.4%
Operating Margin
+5.7%
Net Margin
-176.9%
EPS Growth
-4.9%
Financial Health
Cash/Price Ratio
+3.6%
Current Ratio
0.8x
Debt/Equity
5,409.1x
ROE
-183.6%
ROA
+1.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Claritev Corporation (MPLN) Business Model
About Claritev Corporation
What They Do
Provides advanced technological solutions for data analytics.
Business Model
The company generates revenue by offering analytical tools and platforms that help businesses leverage data for insights, enhancing operational efficiency and decision-making. Its solutions cater to a wide range of clients, from large corporations to startups, across various industries including finance, healthcare, and retail.
Additional Information
Claritev Corporation emphasizes research and development to remain at the forefront of technology, focusing on big data integration, artificial intelligence, and cloud computing. This commitment allows it to significantly contribute to digital transformation and maintain a competitive edge in the market.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
2,700
CEO
Mr. Travis S. Dalton
Country
United States
IPO Year
2020
Website
www.claritev.comClaritev Corporation (MPLN) Latest News & Analysis
Latest News
Quick Summary
ClearNote Health's Avantect Pancreatic Cancer Test is now accessible to members of Claritev's national PHCS and MultiPlan Networks.
Why It Matters
ClearNote Health's Avantect test expansion into major health networks signals increased market access, potentially boosting sales and investor confidence in the company's growth trajectory.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Claritev Corporation (MPLN) held its Q4 2024 earnings call, discussing financial results and outlook for investors. Further details can be found in the full transcript.
Why It Matters
The Q4 2024 earnings call for Claritev Corporation (MPLN) provides insights into financial performance, future guidance, and strategic direction, crucial for assessing investment potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025
2 months ago
Quick Summary
Claritev has reported its fourth quarter and full-year 2024 financial results and provided initial guidance for full-year 2025.
Why It Matters
Claritev's Q4 and full-year 2024 results, along with 2025 guidance, provide insights into financial health and growth prospects, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MultiPlan Corporation (MPLN) reported a quarterly loss of $5.14 per share, exceeding the Zacks Consensus Estimate of a $2.33 loss and widening from a $2.40 loss per share a year prior.
Why It Matters
MultiPlan's larger-than-expected quarterly loss signals worsening financial health, potentially impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Claritev Corporation (NYSE: MPLN) announced that its analytics solution, BenInsights®, has achieved Integrated with Oracle Cloud Expertise and is now available in the Oracle Cloud Marketplace.
Why It Matters
Claritev's BenInsights integration with Oracle Cloud enhances its market position, potentially boosting revenue and attracting new clients, which could positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Claritev Corporation, formerly MultiPlan, will rebrand and begin trading under the ticker CTEV on the NYSE starting February 28, 2025. The company focuses on affordable healthcare solutions.
Why It Matters
Claritev's rebranding and new ticker may signal a strategic shift, impacting investor perception and stock performance ahead of its 2025 trading change.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MPLN Stock
What is Claritev Corporation's (MPLN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Claritev Corporation (MPLN) has a median price target of $10.00. The highest price target is $10.00 and the lowest is $10.00.
Is MPLN stock a good investment in 2025?
According to current analyst ratings, MPLN has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MPLN stock?
Wall Street analysts predict MPLN stock could reach $10.00 in the next 12 months. This represents a -65.7% decrease from the current price of $29.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Claritev Corporation's business model?
The company generates revenue by offering analytical tools and platforms that help businesses leverage data for insights, enhancing operational efficiency and decision-making. Its solutions cater to a wide range of clients, from large corporations to startups, across various industries including finance, healthcare, and retail.
What is the highest forecasted price for MPLN Claritev Corporation?
The highest price target for MPLN is $10.00 from Daniel Grosslight at Citigroup, which represents a -65.7% decrease from the current price of $29.15.
What is the lowest forecasted price for MPLN Claritev Corporation?
The lowest price target for MPLN is $10.00 from Daniel Grosslight at Citigroup, which represents a -65.7% decrease from the current price of $29.15.
What is the overall MPLN consensus from analysts for Claritev Corporation?
The overall analyst consensus for MPLN is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are MPLN stock price projections?
Stock price projections, including those for Claritev Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:49 AM UTC